Lurdes Queimado, MD, PhD

Presbyterian Health Foundation Endowed Chair in ORL; Director of Basic and Translational Research; TSET Research Scholar; Associate Professor, Department of Otorhinolaryngology, University of Oklahoma Health Sciences Center

Dr. Lurdes Queimado earned her Doctor of Medicine  – Summa Cum Laude  – from the University of Lisbon in 1989 and trained as a Surgical Pathology resident at the Portuguese Institute of Oncology, Lisbon, Portugal. She then earned a Master of Science in Oncobiology from the University of Porto, Portugal. In 1994, she became the Leader of the Molecular Pathology Group at the Portuguese Institute of Oncology in Lisbon, Portugal. In 1996, fully funded by the main Portuguese Institute of Health, Dr. Queimado came as a visiting scientist to the University of Texas Southwestern Medical Center at Dallas to complete her own cancer research project. She stayed six years at this institution. During this period, she earned her PhD in Molecular Pathology from the New University of Lisbon, and in 2000 she became a faculty member at UTSW Medical Center at Dallas. Since November 2002, she has held a faculty position and an endowed chair in the Department of Otorhinolaryngology at the University of Oklahoma Health Sciences Center.

Dr. Queimado’s research program focuses on the molecular mechanisms that lead to oncogenesis and determine cancer risk and outcome. The program’s long term goals are to develop personalized preventive and therapeutic strategies. They use in vitro and in vivo models, as well as human patient samples, to decipher the molecular mechanisms by which tobacco cigarettes and other nicotine delivery devices might lead to cancer and therapeutic resistance. Her lab’s studies have major clinical implications and have led to the identification of novel prognostic markers as well as to the development of new drugs targeting cancer stem cells. Recently, they have filled a major methodological gap in the field of DNA damage detection by developing a novel and highly sensitive assay (PADDA) to map and quantify in vivo DNA damage. Funded by NIH, they are now exploring PADDA’s sensitivity and accuracy as a screening tool for head and neck cancer.  Dr. Queimado’s research program has been continuously supported over the past 14 years by grants from the National Institutes of Health (National Cancer Institute), the Adenoid Cystic Carcinoma Research Foundation, the Presbyterian Health Foundation, and the Oklahoma Center for the Advancement of Science and Technology (OCAST).


Degree-Granting Institutions
The New University of Lisbon, Lisbon, Portugal, & University of Texas Southwestern Medical Center at Dallas, PhD, 1998, Molecular Pathology
The University of Porto, Porto, Portugal, MS, 1994, Oncobiology
The University of Lisbon, Portugal, MD, 1989, Medicine

Postgraduate Training
Postdoctoral Fellowship, Department of Pathology, The University of University of Texas Southwestern Medical Center at Dallas, Dallas, TX; Primary Mentor: Errol Friedberg, M.D., 07/1998− 06/2000
Surgical Pathology Residency, Portuguese Institute of Oncology, Lisbon, Portugal. Primary Mentor: Jorge Soares, M.D., 09/1991−08/1992; 08/1994−12/1994
General Medical Residency, Hospital de Santa Maria, University of Lisbon, Lisbon, Portugal, 09/1989−08/1991

Grant Funding:

Wagener, T. (Principal Investigator); Queimado, L. (Co-Investigator), 10% Effort
“Examination of First and Second Generation E-cigarettes”
1R01 CA194158-01, NIH/NCI    
$462,598 annual direct costs

Queimado, L. (Principal Investigator), 35% Effort    
“A novel molecular assay for early detection and assessment of cancer risk”
1 R33 CA202898-01, NIH/NCI     
$248,972 annual direct costs

Benbrook, D. (Principal Investigator); Queimado, L. (Co-Investigator), 2% Effort    “Ovarian Cancer Chemoprevention”    
1 R01 CA196200-01A1, NIH/NCI
$413,410 annual direct costs

Queimado, L (Principal Investigator), 15% Effort    
“Studying the effects of tobacco smoking on oral stem cells”     
HR16-007, OCAST    
$45,000 annual direct costs

Queimado, L. (Principal Investigator), 10% Effort    
“Assessing the effects of electronic cigarette aerosol on oral cancer risk”
Presbyterian Health Foundation (PHF) Bridge Grant,    
$75,000 annual direct costs

Queimado, L. (Principal Investigator), 15% Effort    
“Studying cancer risk and therapy resistance associated with electronic cigarette use”
Oklahoma Tobacco Research Center (OTRC)         
$50,000 annual direct costs

Queimado, L. (Principal Investigator), 5% Effort    
“Validation of a Novel Assay for Quantification of DNA Damage in Cervical Samples”
SCC Gynecologic Cancers Program, Pilot Grant
$40,000 Annual direct costs

Completed Funding (Past 5 years)

Queimado, L. (Principal Investigator), 10% Effort    
“Quantification of DNA Damage Induced by E-cigarettes”

Queimado, L. (Principal Investigator), 25% Effort    
“Predicting Oral Cancer Risk and Treatment Efficacy”
OCAST, HR11-102    

Queimado, L. (Principal Investigator), 10% Effort    
“A Novel Assay to Predict Susceptibility to Tobacco-Induced Disease In Diverse Populations”

El-Naggar (Principal Investigator); Queimado, L. (Consultant)    
National Salivary Gland Tumor and Cell Line Biorepository, UT MD Anderson Cancer Center, Houston, TX

Selected Publications:

Ganapathy V, Manyanga J, Brame L, McGuire D, Sadhasivam B, Floyd E, Rubenstein DA, Ramachandran I, Wagener T, Queimado L. Electronic cigarette aerosols suppress cellular antioxidant defenses and induce significant oxidative DNA damage. PLoS One 2017; 12: e0177780.

Wagener TL, Floyd EL, Stepanov I, Driskill LM, Frank SG, Meier E, Leavens EL, Tackett AP, Molina N, Queimado L. Have combustible cigarettes met their match? The nicotine delivery profiles and harmful constituent exposures of second- and third-generation electronic cigarette users. Tob Control, Online First Oct 11, 2016; doi:10.1136/tobaccocontrol-2016-053041. PMID: 27729564

Drier Y, Cotton MJ, Williamson KE, Gillespie SM, Ryan RJ, Kluk MJ, Carey CD, Rodig SJ, Sholl LM, Afrogheh AH, Faquin WC, Queimado L, Qi J, Wick MJ, El-Naggar AK, Bradner JE, Moskaluk CA, Aster JC, Knoechel B, Bernstein BE. An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nat Genet. 2016 Feb 1. doi: 10.1038/ng.3502.

Ganapathy V, Ramachandran I, Rubenstein D, Queimado L. Detection of in vivo DNA damage induced by very low doses of mainstream and sidestream smoke extracts using a novel assay. Amer J Prev Med, 48 (1 Suppl 1):S102-10, 2015.

Ramachandran I, Ganapathy V, Gillies E, Fonseca I, Sureban SM, Houchen CW, Reis A, Queimado L. Wnt inhibitory factor 1 suppresses cancer stemness and induces cellular senescence. Cell Death Dis. 22;5:e1246, 2014. doi: 10.1038/cddis.2014.219. PMID: 24853424. 

Warner KA, Adams A, Bernardi L, Nor C, Herwig K, Zhang Z, McLean SA, Helman J, Wolf GT, Divi V, Queimado L, Kaye FJ, Castilho R, Nör JE. Tumorigenic human salivary mucoepidermoid carcinoma cell lines. Oral Oncology, 49(11):1059-1066, 2013.

Moxley KM, Benbrook DM, Queimado L, Zuna RE, Thompson D, McCumber M, Premkumar P, Thavathiru E, Hines L, Moore KN. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. Gynecol Oncol. 130(2):377-82, 2013.

Ramachandran I, Thavathiru E, Ramalingam S, Natarajan G, Mills W, Benbrook D, Zuna R, Lightfoot S, Reis AMC, Anant S and Queimado L. Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo. Oncogene, 31:2725–2737, 2012.

Reis AMC, Mills W, Ramachandran I, Friedberg EC, Thompson DM, Queimado L. Targeted detection of in vivo endogenous DNA base damage reveals preferential base excision repair in the transcribed strand. Nucleic Acids Res, 40(1):206-219, 2012.

Queimado L, Obeso D, Hatfield MD, Yang Y, Thompson DM and Reis AMC. Dysregulation of Wnt pathway components in human salivary gland tumors. Arch Otolaryngol Head Neck Surg, 143:94-101, 2008.

Queimado L, Lopes C and Reis AMC. WIF1, an inhibitor of the Wnt pathway, is rearranged in salivary gland tumors. Genes Chromosomes & Cancer, 46:215–225, 2007.

Hatfield MD, Reis AMC, Obeso, D., Cook JR, Thompson D.M., Rao M, Friedberg E.C. and Queimado L. Identification of MMS19 domains with distinct functions in NER and transcription. DNA Repair, 5:914-924, 2006.